Your browser doesn't support javascript.
loading
Long-term Experience of LINAC Single-Dose Radiosurgery for Skull Base Meningiomas: A Retrospective Single-Center Study of 241 Cases.
Ortiz García, Isabel M; Rodríguez Valero, Paula; Jorques Infante, Ana M; Cordero Tous, Nicolás; Expósito Hernández, José; Olivares Granados, Gonzalo.
Afiliação
  • Ortiz García IM; Department of Neurological Surgery, "Virgen de las Nieves" University Hospital, Granada , Spain.
  • Rodríguez Valero P; Department of Neurological Surgery, "Virgen de las Nieves" University Hospital, Granada , Spain.
  • Jorques Infante AM; Department of Neurological Surgery, "Virgen de las Nieves" University Hospital, Granada , Spain.
  • Cordero Tous N; Department of Neurological Surgery, "Virgen de las Nieves" University Hospital, Granada , Spain.
  • Expósito Hernández J; Department of Radiotherapy and Oncology, "Virgen de las Nieves" University Hospital, Granada , Spain.
  • Olivares Granados G; Department of Neurological Surgery, "Virgen de las Nieves" University Hospital, Granada , Spain.
Oper Neurosurg (Hagerstown) ; 25(6): 529-537, 2023 Dec 01.
Article em En | MEDLINE | ID: mdl-37655877
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Stereotactic radiosurgery (SRS) is increasingly applied to treat meningiomas, attributable to their increased incidence in older individuals at greater surgical risk. To evaluate the effectiveness of treatment with linear accelerator (LINAC)-based stereotactic radiosurgery in skull base meningiomas as either primary treatment or postresection adjuvant therapy.

METHODS:

This study included 241 patients diagnosed with skull base meningiomas treated by single-dose SRS, with a median age of 59 years. SRS was primary treatment in 68.1% (n = 164) and adjuvant treatment in 31.9% (n = 77), using LINAC (Varian 600, 6 MeV). The median tumor volume was 3.2 cm 3 , and the median coverage dose was 14 Gy. Bivariate and multivariate analyses were performed to determine predictive factors for tumor progression, clinical deterioration, and complications. Kaplan-Meier analysis was used for survival analysis.

RESULTS:

After the median follow-up of 102 months, the tumor control rate was 91.2% (n = 220). Progression-free survival rates were 97.07%, 90.1%, and 85.7% at 5, 10, and 14 years, respectively. Clinical improvement was observed in 56 patients (23.2%). In multivariate analysis, previous surgery (hazard ratio 3.8 [95%CI 1.136-12.71], P = .030) and selectivity (hazard ratio .21 [95%CI 0.066-0.677], P = .009) were associated with tumor progression and increased maximum dose (odds ratio [OR] 4.19 [95% CI 1.287-13.653], P = .017) with clinical deterioration. The permanent adverse radiation effect rate was 6.2% (n = 15) and associated with maximum brainstem dose >12.5 Gy (OR 3.36 [95% CI .866-13.03], P = .08) and cerebellopontine angle localization (OR 3.93 [95% CI 1.29-11.98], P = .016).

CONCLUSION:

Treatment of skull base meningiomas with single-dose SRS using LINAC is effective over the long term. Superior tumor control is obtained in patients without previous surgery. Adverse effects are related to localization in the cerebellopontine angle, and maximum brainstem radiation dose was >12.5 Gy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiocirurgia / Neoplasias da Base do Crânio / Deterioração Clínica / Neoplasias Meníngeas / Meningioma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiocirurgia / Neoplasias da Base do Crânio / Deterioração Clínica / Neoplasias Meníngeas / Meningioma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article